In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $29.75 up 1.88% from its previous closing price of $29.2. In other words, the price has increased by $1.88 from its previous closing price. On the day, 0.5 million shares were traded. SYRE stock price reached its highest trading level at $29.78 during the session, while it also had its lowest trading level at $28.71.
Ratios:
For a deeper understanding of Spyre Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.90 and its Current Ratio is at 10.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Deutsche Bank on September 26, 2025, initiated with a Buy rating and assigned the stock a target price of $43.
On April 08, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $45.
On March 18, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $27.Wolfe Research initiated its Outperform rating on March 18, 2025, with a $27 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 03 ’25 when Turtle Cameron sold 45,000 shares for $23.33 per share. The transaction valued at 1,049,778 led to the insider holds 701,907 shares of the business.
CAMERON TURTLE bought 90,000 shares of SYRE for $2,201,400 on Nov 03 ’25. On Sep 02 ’25, another insider, Burrows Scott L, who serves as the Chief Financial Officer of the company, sold 18,428 shares for $16.26 each. As a result, the insider received 299,639 and left with 97,994 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 2308365824 and an Enterprise Value of 1977987840.
Stock Price History:
The Beta on a monthly basis for SYRE is 3.12, which has changed by 0.046429873 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $29.50, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 40.10%, while the 200-Day Moving Average is calculated to be 69.03%.
Shares Statistics:
For the past three months, SYRE has traded an average of 844.94K shares per day and 608310 over the past ten days. A total of 77.59M shares are outstanding, with a floating share count of 67.49M. Insiders hold about 13.02% of the company’s shares, while institutions hold 77.01% stake in the company. Shares short for SYRE as of 1763078400 were 12464842 with a Short Ratio of 14.75, compared to 1760486400 on 13390470. Therefore, it implies a Short% of Shares Outstanding of 12464842 and a Short% of Float of 19.399999.
Earnings Estimates
The firm’s stock currently is rated by 10.0 analysts. The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.49 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$0.98 and -$3.37 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$2.68, with 10.0 analysts recommending between -$0.75 and -$4.55.
